Takeda Pharmaceutical Company Limited
TKPHF
$30.58
$0.391.29%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.31B | 672.49M | -80.03M | 860.22M | -676.88M |
| Total Depreciation and Amortization | 3.24B | -1.34B | 1.25B | 1.26B | 3.68B |
| Total Amortization of Deferred Charges | -2.22B | 2.58B | -- | -- | -2.44B |
| Total Other Non-Cash Items | 176.08M | 767.64M | 1.24B | -392.96M | 870.57M |
| Change in Net Operating Assets | 1.57B | -255.21M | 148.76M | -233.34M | 18.85M |
| Cash from Operations | 466.52M | 2.42B | 2.56B | 1.49B | 1.46B |
| Capital Expenditure | -290.21M | -270.14M | -271.88M | -331.74M | -320.17M |
| Sale of Property, Plant, and Equipment | 338.00K | 97.30K | 0.00 | 44.21M | 210.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 3.22M | 20.54M | 2.40M | 202.80M | 71.96M |
| Other Investing Activities | -76.52M | -1.24B | -56.91M | -145.09M | 118.86M |
| Cash from Investing | -363.17M | -1.49B | -326.39M | -229.82M | -129.14M |
| Total Debt Issued | 60.00B | 0.00 | 342.51B | 183.56B | 27.49B |
| Total Debt Repaid | -85.62B | -9.89B | -305.95B | -183.53B | -230.99B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -51.60B | -49.98B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -55.00M | -967.03M | -59.58M | -1.01B | -63.90M |
| Other Financing Activities | -43.09B | -33.53B | -39.75B | -18.02B | -38.57B |
| Cash from Financing | -485.07M | -1.25B | -81.24M | -1.49B | -1.98B |
| Foreign Exchange rate Adjustments | 6.88M | 145.63M | 90.62M | -16.86M | -63.65M |
| Miscellaneous Cash Flow Adjustments | -6.30K | -- | -- | -- | 6.60K |
| Net Change in Cash | -374.85M | -172.27M | 2.25B | -243.06M | -715.32M |